RNASE13
Probable inactive ribonuclease-like protein 13
Also known as: RAL1, RNS13_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q5GAN3
- Gene
- RNASE13
- Ensembl
- ENSG00000206150
- Chromosome
- 14
- Canonical length
- 156 aa
- Protein class
- Predicted secreted proteins
- Secretome location
- Secreted in male reproductive system
OverviewNCBI Gene
Predicted to enable nucleic acid binding activity. Predicted to be involved in defense response to Gram-positive bacterium. Predicted to be located in extracellular region. [provided by Alliance of Genome Resources, Jul 2025]
Canonical amino-acid sequenceUniProt
156 residues, UniProt reviewed canonical sequence.
>Q5GAN3|RNASE13
1 MAPAVTRLLF LQLVLGPTLV MDIKMQIGSR NFYTLSIDYP RVNYPKGFRG YCNGLMSYMR
61 GKMQNSDCPK IHYVIHAPWK AIQKFCKYSD SFCENYNEYC TLTQDSLPIT VCSLSHQQPP
121 TSCYYNSTLT NQKLYLLCSR KYEADPIGIA GLYSGILocalizationUniProt · AlphaFold · HPA
Whether an antibody against RNASE13 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Secreted
- Secreted
- Yes
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.35
- Highest tissue expression
- 290 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 290 nTPM
- salivary gland: 2.8 nTPM
- liver: 0.8 nTPM
- spleen: 0.5 nTPM
- testis: 0.5 nTPM
- skeletal muscle: 0.3 nTPM
Single-cell type
- epididymal principal cells: 5.6 nCPM
- epididymal efferent duct absorptive cells: 0.2 nCPM
- vascular smooth muscle cells: 0.1 nCPM
- adipocytes: 0 nCPM
- adrenal cortex cells: 0 nCPM
- adrenal medulla cells: 0 nCPM
Immune cell
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
- intermediate monocyte: 0 nTPM
- MAIT T-cell: 0 nTPM
Brain region
- basal ganglia: 0.3 nTPM
- amygdala: 0.2 nTPM
- cerebellum: 0.2 nTPM
- cerebral cortex: 0.2 nTPM
- choroid plexus: 0.2 nTPM
- hypothalamus: 0.2 nTPM
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 1.86
- gnomAD pLI
- 0.32
- gnomAD missense Z
- -0.25
- DepMap mean gene effect
- -0.12
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 3% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
KeywordsUniProt
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads RNASE13 as an antibody target. Whether an autoantibody or antibody against RNASE13 could matter depends on whether native RNASE13 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
RNASE13 is annotated as secreted, so native RNASE13 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.
Annotation status
The present source text does not explicitly label RNASE13 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...